In the world of healthcare, the conversation often revolves around the effectiveness of treatments, but an equally critical aspect that deserves our attention is the question of reimbursement. Who pays for these life-saving and life-enhancing interventions? This article delves into the impact of reimbursement on ASX health stocks, exploring how it can make or break a healthcare company's success.
The Reimbursement Factor
Securing reimbursement from governments or insurers is a game-changer for healthcare companies. It provides a stable revenue stream, removing the uncertainty surrounding payment for medical services. This is particularly crucial for small-cap companies on the ASX, as highlighted by Iain Wilkie, a healthcare analyst at Morgans.
"Out-of-pocket expenses matter. Having treatments subsidized by the government or funded by insurance, especially for costly procedures, can significantly impact patients and companies."
Emyria's Success Story
Emyria (ASX: EMD) is a prime example of how reimbursement can unlock growth potential. The company, which operates mental health programs through its Empax clinics, has secured a reimbursement agreement with Medibank Private, Australia's largest private health insurer. This deal covers eligible members accessing Emyria's PTSD and TRD programs, ensuring a steady stream of patients and revenue.
Additionally, the Australian government's Department of Veterans' Affairs (DVA) is funding eligible veterans to access these programs. Dr. Michael Winlo, Emyria's managing director, emphasizes the rising costs of mental health conditions for payers, with Medibank spending over $2 billion on mental health hospitalizations in the past decade alone.
"Payers are interested in new approaches to PTSD and TRD care. They want to track outcomes, ensuring clinical and cost-effectiveness."
Pacific Edge's Challenge
In contrast, Pacific Edge (ASX/NZX: PEB) illustrates the challenges that arise when reimbursement is withdrawn. The company, which develops non-invasive urine-based tests for bladder cancer, experienced a significant drop in revenue after a major Medicare Administrative Contractor (MAC) issued a non-coverage determination for its Cxbladder test.
This led to a decline in operating revenue and an increase in net losses. To fight for reinstatement, Pacific Edge raised funds through institutional and retail placements, demonstrating the company's commitment to regaining Medicare coverage. The recent draft Local Coverage Determination (LCD) issued by Novitas, which establishes haematuria evaluation as a Medicare benefit, is a step in the right direction, allowing the company to claim reimbursement for defined patient populations.
EBR Systems' Medicare Support
EBR Systems (ASX: EBR) is another ASX-listed company benefiting from US Medicare support. Its WiSE system, a wireless cardiac pacing technology, received FDA approval in 2025, followed by Medicare reimbursement by October of the same year. This dual approval cleared the two biggest commercial hurdles for medical devices entering the US market.
The CMS approved a New Technology Add-On Payment (NTAP) for inpatients, providing a substantial top-up above standard Medicare rates, and granted Transitional Pass-Through payment status for outpatient procedures, covering 100% of the device cost. As a result, EBR has seen a significant increase in implant volumes and revenue.
Conclusion
Reimbursement is a critical factor in the success of healthcare companies. It provides a stable financial foundation, allowing companies to focus on innovation and patient care. The stories of Emyria, Pacific Edge, and EBR Systems highlight the impact of reimbursement on growth, revenue, and market presence. As we navigate the complex world of healthcare, understanding the role of reimbursement is essential for investors and stakeholders alike.
